Semax is a research-grade reference peptide supplied strictly for in-vitro and laboratory research use only. It is not for human or animal consumption, is not approved by the FDA, and is not a drug, supplement, cosmetic, or treatment for any cognitive or neurological condition. This page is third-person science education about what researchers investigate when they study Semax in cell cultures and animal models. It does not describe or endorse taking, dosing, or administering any substance, and any health question belongs with a licensed clinician.
What Semax Is
Semax is a synthetic heptapeptide studied as a neuroactive research compound. It was derived from a fragment of adrenocorticotropic hormone (ACTH) but engineered specifically to remove the hormonal, corticotropic activity of the parent molecule, leaving behind the properties that researchers associate with effects on the nervous system. In the literature it is classified among the short regulatory neuropeptides investigated for neuroprotection and neuroplasticity, not among hormones.
On this page Semax is treated entirely as laboratory science. The material supplied by Peptides Factory Direct is a reference compound for controlled research, not a product for personal use. Most of what is known about it comes from Eastern European preclinical work and from cell-culture and rodent studies, and those observations are non-human findings that establish mechanisms rather than outcomes in people. For the underlying biology of how short peptides act as signaling molecules, see the primer on what peptides are and the broader family of cognitive peptides studied in this space.
- Class: short regulatory neuropeptide (heptapeptide) studied in neuroprotection and cognitive research models.
- Research status: reference material for in-vitro and animal study only, never a medicine.
- Origin: engineered from an ACTH fragment with the hormonal activity deliberately removed.
Structure and the ACTH(4-10) Origin
Semax is based on the ACTH(4-10) fragment, a short stretch of the adrenocorticotropic hormone sequence (Met-Glu-His-Phe-Pro-Gly-Pro), with a proline-glycine-proline tail added to improve stability against enzymatic degradation. This structural choice is deliberate and central to why the peptide is studied: the parent ACTH molecule drives cortisol release from the adrenal glands, but the specific fragment used in Semax retains neuromodulatory character while lacking that corticotropic hormonal action.
Separating the neuroactive properties from the hormonal ones gave researchers a cleaner experimental tool. When a compound both signals in the brain and triggers a systemic stress-hormone response, it is difficult to attribute any observed effect to one mechanism. By designing out the corticotropic activity, investigators can study the nervous-system effects of an ACTH-derived sequence without the confound of an adrenal response, which is a large part of the peptide research appeal.
The added terminal residues also extend the peptide half-life in model systems compared with the bare fragment. Like most short peptides it is still relatively short-lived, and that pharmacokinetic reality is one of the properties researchers account for when designing in-vitro and animal studies.
Neurotrophic Factor Research: BDNF and NGF
A dominant research theme for Semax is its influence on neurotrophic factors, the signaling proteins that support the growth, maintenance, and survival of neurons. Preclinical studies have measured whether exposure to the peptide changes expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), along with their receptors, in brain tissue and cultured cells. These factors are standard laboratory readouts for neuroplasticity and neuronal resilience, which is why they anchor so much of the work.
Researchers are interested in this pathway because BDNF and NGF sit upstream of processes such as synapse formation and neuronal repair in model systems. A compound that appears to modulate their expression provides a mechanism worth mapping in detail. As always, an expression change measured in a rodent brain or a cell culture is a molecular observation about a pathway, not a demonstration of a memory, mood, or recovery outcome in any organism.
Neuroprotection and Ischemia Research Models
Semax is frequently studied in models of neuronal stress, particularly cerebral ischemia paradigms where blood supply to brain tissue is experimentally restricted. In these animal and cell-culture models, researchers examine markers of neuronal injury, oxidative stress, inflammatory signaling, and cell survival to ask whether the peptide changes the tissue response to that insult. This is a mechanistic line of inquiry into how the compound interacts with injury-related pathways.
The neuroprotection theme connects back to the neurotrophic work, because the same BDNF and NGF signaling that supports neurons under normal conditions is also implicated in how tissue responds to stress. Investigators study whether Semax influences these overlapping systems in a coordinated way. It bears repeating that ischemia-model findings are non-human results describing a mechanism under study, and nothing on this page should be read as a claim that the compound treats stroke or any injury in people.
Why Injury-Model Findings Stay in the Lab
An observation that a compound reduces an injury marker in an experimental ischemia model does not establish a clinical benefit. Animal and cell-culture injury models are simplified, controlled systems designed to isolate a mechanism, and the gap between such a model and a human condition is wide. Responsible science reports these results as mechanistic leads that justify further study, not as evidence of a treatment effect.
Dopaminergic, Serotonergic, and Enzymatic Themes
Alongside the neurotrophic and neuroprotection work, Semax is studied for effects on monoamine systems. Preclinical research has examined its interaction with dopaminergic and serotonergic signaling in specific brain regions of animal models, measuring neurotransmitter levels and turnover. Because these systems underlie attention, motivation, and mood circuitry, they are natural endpoints for a peptide investigated as a nootropic research tool.
A further mechanistic theme, shared with the related peptide Selank, is enkephalinase inhibition. Enkephalins are the body's natural short opioid-like peptides, and they are degraded rapidly by enzymes. Some studies have asked whether Semax slows that degradation and thereby raises local enkephalin levels in model tissue, offering a route by which the compound could influence mood- and stress-related signaling without acting directly on opioid receptors.
The value of Semax as a research tool lies partly in this breadth: a single molecule that can be examined across neurotrophic, neuroprotective, monoaminergic, and enzymatic pathways. That same breadth makes disciplined controls and verified purity essential, because a multi-pathway compound will produce confounded data if the material itself is not what the label claims.
Handling, Solubility, and Stability
Semax is a short, water-soluble peptide, and laboratories typically reconstitute lyophilized material in sterile or bacteriostatic water for in-vitro work. Because short peptides are sensitive to oxidation, improper pH, and repeated temperature cycling, the dry powder is generally stored cold and reconstituted stock is divided into aliquots to avoid repeated freeze-thaw. The methionine residue in the sequence makes oxidation a particular variable to control, since oxidized methionine can alter how the molecule behaves in an assay.
The arithmetic laboratories use to reach a target working concentration from a known mass of powder can be worked through with the peptide reconstitution calculator, and the practical variables that govern peptide stability across runs are collected in the storage and shelf-life questions. Handling discipline is not a formality here; it is what separates reproducible data from run-to-run noise.
What Researchers Measure
When Semax is used as a research tool, the chosen endpoints track the pathway under investigation. Neurotrophic studies quantify BDNF and NGF expression by messenger RNA and protein assays; neuroprotection studies score cell survival, oxidative-stress markers, and inflammatory signaling in injury models; monoamine studies measure neurotransmitter levels and turnover. In each design the peptide is the independent variable compared against untreated controls.
Equally important, careful studies verify what the compound is before interpreting what it does. Identity by mass spectrometry and purity by HPLC are baseline checks, because any biochemical or behavioral result attributed to Semax is only meaningful if the vial contained the intended seven-residue sequence at a documented purity. Without that verification, a striking result cannot be distinguished from an artifact of an impurity.
Why Purity and a Certificate of Analysis Matter
Research data is only as trustworthy as the material behind it. A Semax preparation contaminated with deletion sequences, oxidized species, synthesis byproducts, or endotoxin can distort every downstream measurement, and for a compound studied across multiple neural pathways a contaminant can generate an apparent effect unrelated to the peptide. Purity is a precondition for valid, reproducible research, not a promotional claim.
A Certificate of Analysis (COA) documents this chain of trust: identity confirmed by mass spectrometry, purity quantified by HPLC, and a lot number linking the paperwork to the physical vial. That linkage lets one experiment be compared against another and attributes any observation to the intended molecule rather than an unverified impurity. The standards behind these documents are detailed in the purity testing and COA questions, and Semax as a research reference material can be sourced through the order page. On regulatory context: Semax is not an approved drug or supplement in the United States, it is handled as a research chemical for laboratory use only, and it is not intended for human or animal consumption.
Create a free research account to view current pricing and bundles and place an order.
Frequently asked questions
What is Semax in a research context?
Semax is a synthetic heptapeptide derived from an ACTH fragment but engineered without the hormonal, corticotropic activity of the parent molecule. In research it is used as a molecular tool to study neurotrophic factor expression, neuroprotection, and monoamine signaling in cell cultures and animal models. It is a research-use-only reference material, not a drug, supplement, or cosmetic, and it is not for human or animal consumption.
How is Semax related to ACTH?
Semax is based on the ACTH(4-10) fragment of adrenocorticotropic hormone, with a stabilizing proline-glycine-proline tail added. The design deliberately keeps the neuromodulatory character of that fragment while removing the corticotropic action that drives cortisol release. This separation gives researchers a tool to study nervous-system effects of an ACTH-derived sequence without the confound of an adrenal stress-hormone response.
Why do Semax studies measure BDNF and NGF?
Brain-derived neurotrophic factor and nerve growth factor are signaling proteins that support neuron growth, maintenance, and survival, and they are standard laboratory readouts for neuroplasticity. Researchers measure whether Semax changes their expression in brain tissue and cultured cells to map which repair- and plasticity-related pathways the peptide touches. Such changes are molecular observations, not demonstrations of a cognitive outcome.
What does the neuroprotection research on Semax involve?
Semax is studied in models of neuronal stress, especially cerebral ischemia paradigms where blood supply is experimentally restricted. Researchers measure markers of neuronal injury, oxidative stress, inflammation, and cell survival to ask how the peptide interacts with injury pathways. These are non-human, controlled-model findings describing a mechanism, and they are not evidence that the compound treats stroke or injury in people.
Is Semax approved for any use?
No. Semax is not approved by the FDA as a drug or supplement in the United States. It is handled as a research chemical supplied for in-vitro and laboratory research use only, and it is not intended for human or animal consumption. Any question about safety or health belongs with a licensed clinician rather than a research-materials supplier.
How does Semax compare with Selank in research?
Both are short Russian-developed neuropeptides studied as research tools, and both are examined for enkephalinase inhibition and neuroactive effects. Semax derives from an ACTH fragment and is heavily studied for neurotrophic factor expression and neuroprotection, while Selank derives from tuftsin and is studied more for anxiolytic behavior and immune modulation. Researchers sometimes compare them to isolate shared versus distinct mechanisms.
How is Semax handled in the laboratory?
As a short, water-soluble peptide, Semax is typically reconstituted in sterile or bacteriostatic water for in-vitro work, with dry powder stored cold and stock kept in aliquots to limit freeze-thaw cycling. Its methionine residue makes oxidation a variable to control, since oxidized methionine can change how the molecule behaves in an assay. Careful handling underpins reproducible results.
Why do purity and a COA matter for Semax?
A research finding is only as reliable as the compound that produced it, and because Semax is studied across multiple neural pathways an impurity can create a misleading signal. A Certificate of Analysis documents identity by mass spectrometry and purity by HPLC, tied to a lot number matching the physical vial. That chain of identity lets experiments be compared and attributes any observation to the intended molecule rather than a contaminant.
All guides · Order research peptides
External references: U.S. Food and Drug Administration · Peptide (Wikipedia)